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Abstract
Background: Previous studies have shown that in platelets of mild Alzheimer Disease (AD)
patients there are alterations of specific APP forms, paralleled by alteration in expression level of
both ADAM 10 and BACE when compared to control subjects. Due to the poor linear relation
among each key-element of beta-amyloid cascade and the target diagnosis, the use of systems able
to afford non linear tasks, like artificial neural networks (ANNs), should allow a better
discriminating capacity in comparison with classical statistics.
Objective: To evaluate the accuracy of ANNs in AD diagnosis.
Methods: 37 mild-AD patients and 25 control subjects were enrolled, and APP, ADM10 and BACE
measures were performed. Fifteen different models of feed-forward and complex-recurrent ANNs
(provided by Semeion Research Centre), based on different learning laws (back propagation, sine-
net, bi-modal) were compared with the linear discriminant analysis (LDA).
Results: The best ANN model correctly identified mild AD patients in the 94% of cases and the
control subjects in the 92%. The corresponding diagnostic performance obtained with LDA was
90% and 73%.
Conclusion: This preliminary study suggests that the processing of biochemical tests related to
beta-amyloid cascade with ANNs allows a very good discrimination of AD in early stages, higher
than that obtainable with classical statistics methods.
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Introduction
Neurodegenerative diseases as Alzheimer Disease (AD)
are posing a tremendous impact on our society. There is
no remission in the progression, and pharmacological
interventions available at present require an early and
accurate identification of the disease [1].
Up to now, the diagnosis of probable and possible AD is
based on neuropsychological evaluation by multidimen-
sional assessments. Differential diagnosis between AD
and other types of dementia is often based on exclusion
[2].
Thus, the possibility to use a biomarker supporting clini-
cal diagnosis would be of great relevance in the early
detection of the disease.
For early AD diagnosis, an ideal diagnostic tool must be
sensitive to earlier cognitive and biological changes, but is
should be able to differentiate among AD, normal aging
and other forms of dementia or pseudo dementia. It
should be reliable, readily applicable and simple [3]. In
the last years, we have identified in easily accessible circu-
lating cells, i.e. platelets, a combination of biological
measurements that possess all characteristic to be consid-
ered as highly accurate biomarkers for AD [4-6]. In plate-
lets it is possible to measure the levels of three molecular
identities key-elements in the amyloid-cascade, namely
Amyloid Precursor Protein (APP) forms as well as beta-
secretase (beta-site- APP cleaving enzyme, BACE1)
enzyme, responsible for amyloidogenic pathway, and
alpha-secretase (ADAM10) responsible for non-amy-
loidogenic metabolism [7,8]. Further, we have demon-
strated a concomitant and congruent modification of
these biochemical parameters in platelets of AD patients
when compared to control subjects [6]. Indeed, in plate-
lets of mild AD patients we were able to show an altera-
tion of specific APP forms, paralleled by a decreased
expression level and activity of ADAM 10 as well as an
increased BACE activity, when compared to control sub-
jects [8].
The simultaneous measurement of these biochemical
parameters can be considered as a useful "combining
strategy" to enhance the accuracy of the biological testing.
However, this approach has intrinsic constrains, related to
the statistical analysis used since classical statistics
approaches suffer from underlying non linearity among
variables.
Artificial Neural Networks (ANNs) are adaptive models
for the analysis of data which are inspired by the function-
ing processes of the human brain. They are systems which
are able to modify their internal structure in relation to a
function objective. They are particularly suited for solving
problems of the non linear type, being able to reconstruct
the approximate rules that put a certain set of data – which
describes the problem being considered – with a set of
data which provides the solution [9].
Thus, the aim of this study was to assess the efficacy of
neural network in correctly classifying control subjects
and mild AD patients only on the basis of peripheral beta-
amyloid cascade biomarkers.
Methods
Subjects
The study was carried out on 37 probable mild AD
patients, and 25 healthy age-matched controls (CON), in
accordance with local clinical research regulations and an
informed consent was obtained. Each subject underwent
a clinical and a standardized neuropsychological assess-
ment for evaluation of cognitive functions, activities of
daily living and behavioral and psychological
disturbances.
Probable AD diagnosis was based on National Institute of
Neurological and Communicative Disorders and Stroke-
Alzheimer's Disease and Related Disorders Association
criteria (NINCDS-ADRDA) [10]. Severity of dementia was
rated according to Clinical Dementia Rating (CDR) scale,
and only patients with CDR≤1 entered the study.
The following exclusion criteria were applied: a) major
depressive disorder, bipolar disorder, schizophrenia, sub-
stance use disorder, or mental retardation according to
DSM-IV criteria; b) cerebro-vascular disorder, hydroceph-
alus, and intra-cranial mass, documented by CT or MRI
within the last 12 months; c) abnormalities in serum
folate and vitamin B12, syphilis serology, or thyroid hor-
mones' levels; d) a history of traumatic brain injury or
other neurological disease; e) significant medical prob-
lems (e.g. diabetes or hypertension; cancer; hepatic, renal,
cardiac or pulmonary disorders).
Further, subjects on psychotropic agents, nootropic drugs,
cholinergic or anticholinergic agents, antiplatelets agents,
anticoagulants, steroids, and serotoninergic drugs, were
excluded unless they entered a wash-out phase lasting at
least 14 days before blood collection.
Platelets collection and Western blot analysis
Blood drawing occurred while fasting at 9.00–10.00 AM.
A blood sample (27 ml) was taken, releasing the tourni-
quet, using a 19-gauge needle, and processed as previ-
ously described (6). Platelets were processed for Western
blot analysis (WB) with monoclonal antibody (mAb)
22C11 dilution 1:2000 (Chemicon, Tamecula) raised
against the N-terminal domain of APP, therefore recogniz-
ing the three APP forms with apparent molecular weightJournal of Translational Medicine 2005, 3:30 http://www.translational-medicine.com/content/3/1/30
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of 130, 110, and 106 kDa. The results were expressed as
the ratio (APP ratio) of the optical density of the upper
(130 kDa) to the lower (106–110 kDa) immunoreactive
bands. WB was also performed with polyclonal antibody
(pAb) to ADAM10 dilution 1:1000 (Proscience Inc.,
Poway, CA USA); pAb to BACE 1:500 (Affinity Biorea-
gents Inc., Golden, CO USA), clone AC40 for β-ACTIN
1:3000 (Sigma-Aldrich Steinheim, Germany) were used.
Immunostaining  β-ACTIN, a constitutive protein, was
used as internal standard. The OD between ADAM 10 and
β-ACTIN was measured. Similarly, BACE analysis was per-
formed, and the OD of the two forms (BACE 36 kDa/
BACE 57 kDa) was evaluated.
Quantitative analysis of WB was performed by means of
computer assisted imaging (Quantity-OneR System; Bio-
rad, CA, USA).
Artificial Neural Networks
In this study, we applied supervised ANNs, networks in
which the result of the processing (the output desired) is
already defined. Supervised ANNs calculate an error func-
tion that measures the distance between the desired fixed
output (target) and their own output, and adjust the con-
nection strengths during the training process to minimize
the result of the error function. The learning constraint of
the supervised ANNs is having their own output coincide
with the determined target. The general form of these
ANNs is: y = f(x,w*), where w* constitutes the set of
parameters which best approximate the function. The
ANNs used in the study are characterized by the law of
learning and topology. The laws of learning identify equa-
tions which translate the ANNs inputs into outputs, and
rules by which the weights are modified to minimize the
error or the internal energy of the ANNs.
The topology identifies the structure of the nodes of ANNs
connections and the signal's flow within it. ANNs can be
further distinguished by two broad categories: feed-for-
ward ANNs (FF), in which the signal proceeds from the
input to the output of the ANNs, crossing all of the nodes
only once; recurring ANNs, in which the signal is subject
to specific feedback, determined beforehand, or tied to
the occurrence of particular conditions.
The experiments carried out anticipate the use of both
ANNs and Artificial Organisms, i.e. complex combina-
tions of more networks. Supervised software (Semeion ©),
which allows the combination of each law of learning
with each type of topology, was used for all the testing.
Four models of ANNs and one statistical model used in
the study, as follows.
1) The Back Propagation standard (BP-FF) is defined by dif-
ferent interconnected layers of nodes characterized by a
non linear function, generally of the sigmoidal type [11].
2) The Sine Net (SN) (Semeion ©) is characterized by the
organization of nodes in layers [12]. The fundamental dif-
ference with respect to the better known BP-FF is due to
the characteristics of the function realized by each single
node. In fact, the node activation function, which has sim-
ilar characteristics to those of the BP-FF, operates on an
input that is made up of a sum of sines, each characterized
by its own frequency (the weight of the link/connection).
This modification on the base structure of the node has
profound consequences on the behaviors of the SN both
for the function's calculated properties and for the learn-
ing process modalities.
3) The Bi-Modal networks (BM) (Semeion ©) are multi-lay-
ered networks like Sn and Bp, but differ from these
because of the equations which characterize them [13].
Each hidden node is realized by 2 sub-nodes, each
equipped with its own input connections: the first sub-
node operates according to the descending gradient tech-
nique, the second through vectorial quantification. The
outputs of the two nodes are then composed in a single
output value. These networks therefore originate from the
hybridization of the two most relevant learning mecha-
nisms in the sphere of artificial intelligence: the descend-
ing gradient and the vectorial quantification. The Bi-
Modal demonstrates an excellent convergence capacity on
complex problems; furthermore it does not suffer from
problems on local minimums shown by other algorithms,
which use the principal of the descending, gradient
exclusively.
4) The Soft Max Discriminant Analysis (SMDA) is an ANNs
model composed by a single layer of units, without the
layer of hidden units, where the Soft-Max function is
applied to the output layer.
Statistical models
Results obtained with the neural networks cited above
have been compared with a model of linear statistic, i.e.
the Linear Discriminant Analysis (LDA) (Software SPSS®).
The validation protocol is a fundamental procedure to
verify the models' ability to generalize the results reached
in the testing phase. Among the different protocols
reported in literature, the selected model is the protocol
with the greatest generalization ability on data unknown
to the model itself. The dataset was randomly subdivided
into two sub-samples: the first called Training Set, and the
second, called Testing Set; a fixed ANN (and/or Organ-
ism) which is trained on the Training Set was chosen. In
this phase, the ANN learns to associate the input variablesJournal of Translational Medicine 2005, 3:30 http://www.translational-medicine.com/content/3/1/30
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with those that are indicated as targets; the weight matrix
produced by the ANNs at the end of the training phase
was saved, and freezed with all parameters used for the
training; finally, each case belonging to the Testing Set was
shown to the ANN, in order to allow the ANN to express
an evaluation based on the training just performed. This
procedure takes place for each input vector but every
result (output vector) is not communicated to the ANN; in
this way, the ANN is evaluated only in reference to the
generalization ability that it has acquired during the
Training phase.
Then, a new ANN with identical architecture to the previ-
ous one was constructed and the procedure from point 1
was repeated.
This general training plan has been further developed to
increase the level of reliability of the generalization of the
processing models. The experiments have been done
using a random criterion of distribution of the samples.
We have employed the 5 × 2 cross-validation protocol,
which produces 10 elaborations for every sample. It con-
sists in dividing the sample five times in two sub samples,
containing each similar distribution of cases and controls
[14].
Results
Descriptive Analysis
Control subjects and mild AD patients were comparable
as far as age and gender distribution (see Table 1).
Figure 1 reports a representative Western Blot of APP
forms, ADAM10, and BACE levels in 2 control subjects
and in 2 mild AD patients, the latter showing an alteration
of these three measures. As shown, the optical density of
the upper (130 kDa) APP form was reduced in AD
patients compared to controls, being APP ratio decreased
in the former group (panel A). Moreover, a reduction in
the optical density ratio between ADAM10 and internal
standard control (actin) as well as between the 36 kDa
and the 57 kDa BACE forms was demonstrated in AD (see
panel B,C). A significant statistical difference was present
in APP ratio, BACE and ADM10 values between the two
groups (see Table 1).
The statistical significance of the differences reached an
higher value for ADAM 10 in comparison with BACE and
APP respectively, essentially due to a minor coefficient of
variation index and a higher correlation index value (R2 =
0.012) with the target variable (diagnostic class).
Despite these average differences there was a certain
degree of overlap of beta amyloid markers values across
the two study groups, which made difficult the precise dis-
tinction among individual subjects belonging to one of
the two classes.
ANNs Analysis
In this study two kinds of protocols with neural networks
models have been carried out in order to distinguish indi-
vidual control subjects from mild AD patients only on the
basis of APP, BACE1 and ADAM 10 values. In the first pro-
Table 1: Demographic, clinical and biological variables of the 
subjects.
Variables CONTROLS Mild AD p
Number 25 37 -
Age, years 66.5 ± 3.8 67.3 ± 6.8 n.s.
Gender, M/F 11/14 17/20 n.s.
MMSE score 29.6 ± 1.0 24.9 ± 4.4 .0001
CDR score - 0.7 ± 0.28 .0001
APPr 0.61 ± 0.22 0.44 ± 0.18 .003
BACE 1.52 ± 1.27 0.84 ± 0.73 .008
ADAM 10 0.79 ± 0.49 0.43 ± 0.23 .0004
M: male; F: female; MMSE: Mini-Mental State Examination; CDR: 
Clinical Dementia Rating; APPr: Amyloid Precursor Protein ratio.
Representative Western Blot analysis of APP forms (panel  A), ADAM10 (panel B), and BACE (panel C) in AD patients  and in healthy controls Figure 1
Representative Western Blot analysis of APP forms (panel 
A), ADAM10 (panel B), and BACE (panel C) in AD patients 
and in healthy controls.Journal of Translational Medicine 2005, 3:30 http://www.translational-medicine.com/content/3/1/30
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tocol, which included 170 analyses, APP, BACE and
ADAM10 constituted the input variables. In the second
protocol, which included 150 analyses, the three possible
dual combinations of parameters constituted the input
variables (APP – BACE; APP – ADAM10; BACE – ADAM)
Table 2 summarizes the average results related to 10 inde-
pendent analyses with each different ANN model using
three input variables and 5 × 2 cross-validation protocol.
The best result was obtained with Self Recurrent Network
Dynamic Sine Net (SelfDASn) model, which reached an
overall arithmetic mean accuracy rate of 93.08%. The cor-
Table 2: Three input variables analyses and 5 × 2 cross-validation protocol (average results obtained in 10 analyses with each model). 
LDA: Linear Discriminant Analysis, No: Number; SD: Standard Deviation.
MODELS No. Senitivity Specificity Mean 
Accuracy
No. Errors SD Mean 
Accuracy
p
SelfDASn 10 94,03% 92,12% 93,08% 2,1 2,98 0,000036
TasmDASn 10 95,12% 90,51% 92,82% 2,1 3,26 0,000016
TasmSASn 10 92,51% 91,99% 92,25% 2,4 2,67 0,000022
SelfSASn 10 94,50% 89,87% 92,19% 2,3 2,58 0,000020
TasmDABm 10 93,54% 88,91% 91,23% 2,6 2,84 0,000007
TasmDABp 10 93,51% 88,91% 91,21% 2,6 3,20 0,000001
SelfSABm 10 93,57% 88,14% 90,86% 2,7 3,76 0,000144
SelfDABp 10 92,43% 88,14% 90,29% 2,9 3,35 0,000031
TasmSABp 10 90,79% 88,98% 89,88% 3,1 3,14 0,000302
SelfDABm 10 91,34% 88,21% 89,78% 3,1 4,02 0,000398
TasmSABm 10 91,90% 87,37% 89,64% 3,1 4,07 0,000504
SelfSABp 10 90,29% 88,91% 89,60% 3,2 2,96 0,000311
FF_Sn 10 91,90% 84,17% 88,03% 3,5 4,11 0,000734
FF_Bm 10 88,63% 86,54% 87,58% 3,8 3,61 0,000860
FF_Bp 10 88,63% 85,77% 87,20% 3,9 3,72 0,001092
SMDA 10 89,71% 78,65% 84,18% 4,6 6,31 0,021734
LDA 10 90,26% 72,95% 81,61% 5,2 5,47 -
Table 3: Two variables analyses and 5 × 2 cross-validation protocol (average results obtained in 10 analyses with each model).
INPUT MODELS No. Sensitivity Specificity Mean 
Accuracy
No. Errors SD Mean 
Accuracy
APP ADAM FF_Sn 10 92,98% 76,99% 84,99% 4,2 4,23
FF_Bm 10 93,51% 73,08% 83,29% 4,6 6,06
FF_Bp 10 89,12% 74,74% 81,93% 5,2 5,27
SMDA 10 87,98% 69,17% 78,58% 6,1 6,12
LDA 10 82,52% 63,46% 72,99% 7,8 8,74
APP BACE FF_Sn 10 84,33% 80,06% 82,20% 5,4 3,53
FF_Bm 10 81,69% 79,94% 80,82% 5,9 4,24
FF_Bp 10 83,27% 79,17% 81,22% 5,7 3,92
SMDA 10 82,81% 76,60% 79,70% 6,1 4,21
LDA 10 79,53% 64,68% 72,11% 8,2 4,54
ADAM BACE FF_Sn 10 86,52% 80,19% 83,36% 5 5,91
FF_Bm 10 86,02% 76,92% 81,47% 5,5 5,60
FF_Bp 10 84,88% 79,42% 82,15% 5,4 6,61
SMDA 10 83,86% 74,61% 79,24% 6,2 7,05
LDA 10 85,97% 63,53% 74,75% 7,2 6,76
LDA: Linear Discriminant Analysis, No: Number; SD: Standard Deviation.Journal of Translational Medicine 2005, 3:30 http://www.translational-medicine.com/content/3/1/30
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responding result obtained with Linear Discriminant
Analysis (LDA) was equal to 81.6%.
In Table 3 the average results related to 10 independent
analyses with each different ANN model using two input
variables and 5 × 2 cross-validation protocol are reported.
In these analyses, Feed-Forward ANN models based on
three learning laws (Back-Propagation, SineNet e BiMo-
dal) have been employed in order to define more precisely
the contribution of each marker in discriminating AD.
The comparison with LDA was performed as well, being
the accuracy of ANN higher. The differential performance
rate between ANNs and LDA was the following 12% for
APP+ADAM (FF-Sn 84.99% – LDA 72.99%), 10.09% for
APP+BACE (FF-Sn 82.20% – LDA 72.11%), and 8.61%
for ADAM+BACE (FF-Sn 83.36% – LDA 74.75%).
In the three variables protocol, the corresponding differ-
ential value obtained with the best feed forward ANNs
was equal to 6.42% (FF-Sn 88.03% – LDA 81.61%)
Input relevance analysis
In addition to evaluate the overall performance rate in dis-
criminating between target classes, the AAN models allow
the definition of the net relevance of each input in the
occurring model. This evaluation has been performed
using the seven best performers ANN models (overall
accuracy higher than 97% in blind testing). As reported in
Table 4, the input relevance value referred to each inde-
pendent marker was reported. APP ratio resulted to be the
most relevant variable in one model, thus reaching the
41%, while ADAM10 and BACE showed the highest input
relevance three times each.
Discussion
The main finding of this study is that the application of
artificial neural networks on a set of biomarkers for AD,
designed on the amyloid cascade, improved by more than
10% the accuracy of the early diagnosis of the disease.
The potential medical application of diagnostic biomark-
ers has generated much excitement within the biomedical
community for early disease diagnosis in AD. Several
biomarkers have been proposed in the last years as prom-
ising candidates to assess AD susceptibility among indi-
vidual at risk for the disease.
In recent years, we have assisted to the transition from a
single biomarker to a multiple biomarkers approach [15].
The simultaneous use of different biomarkers, each of
them exploring a component of a complex patho-physio-
logical pathway, has the intrinsic advantage to capture
more information linked to the disease under study com-
pared to a single biomarker approach. The concomitant
use of different factors may decrease the risk of random
variation of single factor obscuring the true signal.
Many medical decisions are made in situations in which
multiple factors must be weighted. Because multiple pre-
dictive features may interact and correlate with outcomes
in complex ways, effective statistical and modeling tools
are needed to integrate these data and to determine their
implications. This is also true for biomarkers use. When
single factor approach is applied to the analysis of multi-
markers data, only one factor (marker) is varied at time,
with the others factors held constant. This is the case of
classical multivariable statistical techniques. With these
techniques the combined interpretation of a given set of
potential predictors with respect to individual patients
may be difficult. This is mainly due to the limitations
imposed by the underlying non-linearities and to com-
plex interactions between the factors under study.
Neural networks can input multiple factors simultane-
ously, combining and recombining them in different
ways according to specific (generally non linear) equa-
Table 4: The input relevance value referred to each independent marker (in bold).
Input relevance values
ANN model Sensitivity Specificity Mean 
Accuracy
No. errors APP BACE ADAM
SelfDASn 94,74% 100,00% 97,37% 1/32 0,4155 0,3001 0,2845
TasmDASn 94,74% 100,00% 97,37% 1/32 0,2528 0,2445 0,5026
SelfDABm 94,44% 100,00% 97,22% 1/30 0,2802 0,4074 0,3124
SelfDABp 94,44% 100,00% 97,22% 1/30 0,2084 0,4285 0,3631
SelfDASn 94,44% 100,00% 97,22% 1/30 0,3653 0,2598 0,3749
SelfSABm 94,44% 100,00% 97,22% 1/30 0,2769 0,4273 0,2958
SelfSASn 94,44% 100,00% 97,22% 1/30 0,3577 0,2486 0,3937Publish with BioMed Central    and   every 
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tions. Thus, the higher predictive values obtained by AAN
could be explained because of the consideration of
parameters which might not reach significance for the
entire population, but are highly significant within sub-
groups. On the other hand, the conventional statistics
reveal only parameters which are significant for the entire
population.
The adaptive systems had superior accuracy when com-
pared to models of classic linear statistics. In fact, assess-
ing the presence of AD, ANNs were more efficient than
conventional statistical analysis, e.g. discriminant analy-
sis, achieving a correct performance (diagnosis) in
extremely high percentage of subjects on average and
reaching a predictive accuracy of 93% when the best net
was used.
Recently, the hypothesis to use a combination of bio-
chemical tests in order to improve the discrimination of
AD in early stages has been put forward [8].
The use of ANNs for detecting association between biolog-
ical markers and disease susceptibility has recently
attracted the attention of the scientific and clinical com-
munity [16,17]. In fact, to enhance diagnostic accuracy
combining tests should be considered to increase the dis-
criminative power of the analysis. In this regard, two dif-
ferent strategies might be followed: either combining tests
related to different patho-physiological pathways or asso-
ciating biomarkers linked to the same biological cascade.
Here we showed that AAN models allow to evaluate three
key-elements of amyloid cascade for diagnostic purpose,
reaching sensitivity and specificity values higher than
those obtained in clinical practice. Studies performed on
a large sample with very mild AD patients, pre-sympto-
matic subjects or patients with other kind of dementia,
will be useful to confirm the diagnostic value of this
approach.
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